Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Anti-tuberculosis Therapeutics Market by Type (Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Otherr), By Application (Hospitals and Clinics, Government Agencies, Non-Profit Organizations, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Anti-tuberculosis Therapeutics Market by Type (Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Otherr), By Application (Hospitals and Clinics, Government Agencies, Non-Profit Organizations, Others) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 168346 3300 Medical Devices & Consumables 377 231 Pages 4.5 (37)
                                          

Market Overview:


The global anti-tuberculosis therapeutics market is expected to grow at a CAGR of 5.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of tuberculosis (TB) and rising awareness about TB prevention and treatment. Based on type, the global anti-tuberculosis therapeutics market is segmented into isoniazid, rifampin, ethambutol, pyrazinamide, and other drugs. Isoniazid is the most commonly prescribed drug for TB treatment and accounted for the majority share of this market in 2017. Based on application, the global anti-tuberculosis therapeutics market is segmented into hospitals and clinics, government agencies, non-profit organizations, and others (including research institutes). Hospitals and clinics accounted for the majority share of this market in 2017.


Global Anti-tuberculosis Therapeutics Industry Outlook


Product Definition:


Anti-tuberculosis therapeutics are a class of drugs used to treat tuberculosis. They include antibiotics such as isoniazid, rifampin, and pyrazinamide, as well as antituberculosis agents such as para-aminosalicylic acid and capreomycin. The use of anti-tuberculosis therapeutics is important for the treatment of tuberculosis.


Isoniazid:


Isoniazid is an anti-tuberculosis drug and is used in the treatment of Tuberculosis (TB). It works by killing the bacteria that causes TB. According to WHO, 1.3 million people die from TB every year with 90% of cases occurring in developing countries. Isoniazid has been found to be more effective than other drugs at treating latent and active tuberculosis; it also has a better safety profile as there are no serious side effects associated with it.


Rifampin:


Rifampin is an antibiotic drug and is used in the treatment of tuberculosis. It works by killing the bacteria that causes tuberculosis. Rifampin can be given with rifamycin or without rifamycin, but it's usually given with other TB drugs because it has better pharmacokinetics when used alone.


Application Insights:


The others segment held the largest share of the global anti-tuberculosis therapeutics market in 2017. This is due to factors such as availability of drugs with fewer side effects and low cost, which makes them affordable for all patients irrespective of their financial condition. The hospital and clinic application segment is expected to witness lucrative growth over the forecast period owing to increasing prevalence of tuberculosis across countries including India, China, Brazil, South Africa and Russia among others. For instance, according to WHO estimates published in 2018; around 10 million people are estimated to be suffering from TB globally while 1 million die due to this disease every year.


Regional Analysis:


North America dominated the global market in 2017. The region is expected to maintain its position throughout the forecast period owing to high government spending on anti-tuberculosis drugs, increasing prevalence of multi-drug resistant tuberculosis, and rising incidence of HIV. In addition, growing number of FDA approvals for new products and increasing healthcare expenditure are also contributing towards growth in this region.


Asia Pacific is estimated to be the fastest growing regional market from 2018 to 2030 due to factors such as economic development & improvement leading toward reduction in poverty lines; increase in disposable income; rise in consumer awareness regarding treatment options; increase medical tourism due to availability of effective treatments at affordable costs coupled with favorable government policies aimed at improving access for patients & promoting public health.


Growth Factors:


  • Increasing incidence of tuberculosis (TB) across the globe
  • Growing awareness about the disease and its treatment options
  • Rising demand for better and more effective anti-tuberculosis drugs
  • Government initiatives and funding for TB research and development programs
  • Technological advancements in the field of anti-tuberculosis therapeutics

Scope Of The Report

Report Attributes

Report Details

Report Title

Anti-tuberculosis Therapeutics Market Research Report

By Type

Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Otherr

By Application

Hospitals and Clinics, Government Agencies, Non-Profit Organizations, Others

By Companies

Lupin, Macleods Pharmaceuticals, Otsuka Pharmaceutical, Johnson & Johnson, Pfizer, Novartis, Abbott, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Merck, Sanofi

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

231

Number of Tables & Figures

162

Customization Available

Yes, the report can be customized as per your need.


Global Anti-tuberculosis Therapeutics Market Report Segments:

The global Anti-tuberculosis Therapeutics market is segmented on the basis of:

Types

Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Otherr

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Hospitals and Clinics, Government Agencies, Non-Profit Organizations, Others

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. Lupin
  2. Macleods Pharmaceuticals
  3. Otsuka Pharmaceutical
  4. Johnson & Johnson
  5. Pfizer
  6. Novartis
  7. Abbott
  8. AstraZeneca
  9. Bayer
  10. Eli Lilly
  11. GlaxoSmithKline
  12. Merck
  13. Sanofi

Global Anti-tuberculosis Therapeutics Market Overview


Highlights of The Anti-tuberculosis Therapeutics Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Isoniazid
    2. Rifampin
    3. Ethambutol
    4. Pyrazinamide
    5. Otherr
  1. By Application:

    1. Hospitals and Clinics
    2. Government Agencies
    3. Non-Profit Organizations
    4. Others
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Anti-tuberculosis Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Anti-tuberculosis Therapeutics Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Anti-tuberculosis therapies are medications used to treat tuberculosis. These therapies can help to stop the spread of tuberculosis, and may also help to improve the symptoms of tuberculosis.

Some of the key players operating in the anti-tuberculosis therapeutics market are Lupin, Macleods Pharmaceuticals, Otsuka Pharmaceutical, Johnson & Johnson, Pfizer, Novartis, Abbott, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, Merck, Sanofi.

The anti-tuberculosis therapeutics market is expected to register a CAGR of 5.8%.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Anti-tuberculosis Therapeutics Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Anti-tuberculosis Therapeutics Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Anti-tuberculosis Therapeutics Market - Supply Chain
   4.5. Global Anti-tuberculosis Therapeutics Market Forecast
      4.5.1. Anti-tuberculosis Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Anti-tuberculosis Therapeutics Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Anti-tuberculosis Therapeutics Market Absolute $ Opportunity

5. Global Anti-tuberculosis Therapeutics Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Anti-tuberculosis Therapeutics Market Size and Volume Forecast by Type
      5.3.1. Isoniazid
      5.3.2. Rifampin
      5.3.3. Ethambutol
      5.3.4. Pyrazinamide
      5.3.5. Otherr
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Anti-tuberculosis Therapeutics Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Anti-tuberculosis Therapeutics Market Size and Volume Forecast by Application
      6.3.1. Hospitals and Clinics
      6.3.2. Government Agencies
      6.3.3. Non-Profit Organizations
      6.3.4. Others
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Anti-tuberculosis Therapeutics Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Anti-tuberculosis Therapeutics Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Anti-tuberculosis Therapeutics Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Anti-tuberculosis Therapeutics Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Anti-tuberculosis Therapeutics Demand Share Forecast, 2019-2026

9. North America Anti-tuberculosis Therapeutics Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Anti-tuberculosis Therapeutics Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Anti-tuberculosis Therapeutics Market Size and Volume Forecast by Application
      9.4.1. Hospitals and Clinics
      9.4.2. Government Agencies
      9.4.3. Non-Profit Organizations
      9.4.4. Others
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Anti-tuberculosis Therapeutics Market Size and Volume Forecast by Type
      9.7.1. Isoniazid
      9.7.2. Rifampin
      9.7.3. Ethambutol
      9.7.4. Pyrazinamide
      9.7.5. Otherr
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Anti-tuberculosis Therapeutics Demand Share Forecast, 2019-2026

10. Latin America Anti-tuberculosis Therapeutics Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Anti-tuberculosis Therapeutics Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Anti-tuberculosis Therapeutics Market Size and Volume Forecast by Application
      10.4.1. Hospitals and Clinics
      10.4.2. Government Agencies
      10.4.3. Non-Profit Organizations
      10.4.4. Others
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Anti-tuberculosis Therapeutics Market Size and Volume Forecast by Type
      10.7.1. Isoniazid
      10.7.2. Rifampin
      10.7.3. Ethambutol
      10.7.4. Pyrazinamide
      10.7.5. Otherr
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Anti-tuberculosis Therapeutics Demand Share Forecast, 2019-2026

11. Europe Anti-tuberculosis Therapeutics Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Anti-tuberculosis Therapeutics Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Anti-tuberculosis Therapeutics Market Size and Volume Forecast by Application
      11.4.1. Hospitals and Clinics
      11.4.2. Government Agencies
      11.4.3. Non-Profit Organizations
      11.4.4. Others
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Anti-tuberculosis Therapeutics Market Size and Volume Forecast by Type
      11.7.1. Isoniazid
      11.7.2. Rifampin
      11.7.3. Ethambutol
      11.7.4. Pyrazinamide
      11.7.5. Otherr
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Anti-tuberculosis Therapeutics Demand Share, 2019-2026

12. Asia Pacific Anti-tuberculosis Therapeutics Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Anti-tuberculosis Therapeutics Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Anti-tuberculosis Therapeutics Market Size and Volume Forecast by Application
      12.4.1. Hospitals and Clinics
      12.4.2. Government Agencies
      12.4.3. Non-Profit Organizations
      12.4.4. Others
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Anti-tuberculosis Therapeutics Market Size and Volume Forecast by Type
      12.7.1. Isoniazid
      12.7.2. Rifampin
      12.7.3. Ethambutol
      12.7.4. Pyrazinamide
      12.7.5. Otherr
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Anti-tuberculosis Therapeutics Demand Share, 2019-2026

13. Middle East & Africa Anti-tuberculosis Therapeutics Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Anti-tuberculosis Therapeutics Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Anti-tuberculosis Therapeutics Market Size and Volume Forecast by Application
      13.4.1. Hospitals and Clinics
      13.4.2. Government Agencies
      13.4.3. Non-Profit Organizations
      13.4.4. Others
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Anti-tuberculosis Therapeutics Market Size and Volume Forecast by Type
      13.7.1. Isoniazid
      13.7.2. Rifampin
      13.7.3. Ethambutol
      13.7.4. Pyrazinamide
      13.7.5. Otherr
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Anti-tuberculosis Therapeutics Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Anti-tuberculosis Therapeutics Market: Market Share Analysis
   14.2. Anti-tuberculosis Therapeutics Distributors and Customers
   14.3. Anti-tuberculosis Therapeutics Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. Lupin
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Macleods Pharmaceuticals
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Otsuka Pharmaceutical
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Johnson & Johnson
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Pfizer
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Novartis
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Abbott
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. AstraZeneca
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Bayer
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Eli Lilly
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. GlaxoSmithKline
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. Merck
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. Sanofi
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us